Lixte Biotechnology Holdings Stock Return On Equity

LIXT Stock  USD 2.07  0.44  26.99%   
Lixte Biotechnology Holdings fundamentals help investors to digest information that contributes to Lixte Biotechnology's financial success or failures. It also enables traders to predict the movement of Lixte Stock. The fundamental analysis module provides a way to measure Lixte Biotechnology's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Lixte Biotechnology stock.
Last ReportedProjected for Next Year
Return On Equity(1.27)(1.34)
Return On Equity is likely to drop to -1.34 in 2024.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Lixte Biotechnology Holdings Company Return On Equity Analysis

Lixte Biotechnology's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.

Return On Equity

 = 

Net Income

Total Equity

More About Return On Equity | All Equity Analysis

Current Lixte Biotechnology Return On Equity

    
  -1.63  
Most of Lixte Biotechnology's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Lixte Biotechnology Holdings is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Lixte Return On Equity Driver Correlations

Understanding the fundamental principles of building solid financial models for Lixte Biotechnology is extremely important. It helps to project a fair market value of Lixte Stock properly, considering its historical fundamentals such as Return On Equity. Since Lixte Biotechnology's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Lixte Biotechnology's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Lixte Biotechnology's interrelated accounts and indicators.
0.96-0.97-0.760.241.0-0.30.460.91-0.660.350.580.950.94-0.110.01
0.96-1.0-0.840.210.96-0.40.420.88-0.710.340.640.980.98-0.35-0.27
-0.97-1.00.83-0.22-0.970.38-0.43-0.890.72-0.34-0.63-0.97-0.970.320.23
-0.76-0.840.83-0.45-0.750.38-0.51-0.720.71-0.69-0.41-0.81-0.820.590.43
0.240.21-0.22-0.450.240.130.660.25-0.010.480.040.160.17-0.12-0.06
1.00.96-0.97-0.750.24-0.290.460.91-0.660.340.580.950.94-0.10.01
-0.3-0.40.380.380.13-0.290.16-0.450.18-0.21-0.66-0.45-0.460.510.38
0.460.42-0.43-0.510.660.460.160.29-0.540.29-0.130.410.40.0-0.02
0.910.88-0.89-0.720.250.91-0.450.29-0.530.470.660.90.89-0.18-0.04
-0.66-0.710.720.71-0.01-0.660.18-0.54-0.53-0.3-0.05-0.7-0.70.30.22
0.350.34-0.34-0.690.480.34-0.210.290.47-0.30.060.350.35-0.3-0.09
0.580.64-0.63-0.410.040.58-0.66-0.130.66-0.050.060.660.67-0.38-0.29
0.950.98-0.97-0.810.160.95-0.450.410.9-0.70.350.661.0-0.3-0.22
0.940.98-0.97-0.820.170.94-0.460.40.89-0.70.350.671.0-0.34-0.27
-0.11-0.350.320.59-0.12-0.10.510.0-0.180.3-0.3-0.38-0.3-0.340.89
0.01-0.270.230.43-0.060.010.38-0.02-0.040.22-0.09-0.29-0.22-0.270.89
Click cells to compare fundamentals
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
Competition

Lixte Total Stockholder Equity

Total Stockholder Equity

4.19 Million

At this time, Lixte Biotechnology's Total Stockholder Equity is comparatively stable compared to the past year.
Based on the latest financial disclosure, Lixte Biotechnology Holdings has a Return On Equity of -1.6333. This is 93.19% lower than that of the Biotechnology sector and 95.52% lower than that of the Health Care industry. The return on equity for all United States stocks is notably higher than that of the company.

Lixte Return On Equity Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Lixte Biotechnology's direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Lixte Biotechnology could also be used in its relative valuation, which is a method of valuing Lixte Biotechnology by comparing valuation metrics of similar companies.
Lixte Biotechnology is currently under evaluation in return on equity category among its peers.

Lixte Biotechnology ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Lixte Biotechnology's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Lixte Biotechnology's managers, analysts, and investors.
Environmental
Governance
Social

Lixte Fundamentals

About Lixte Biotechnology Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Lixte Biotechnology Holdings's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lixte Biotechnology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lixte Biotechnology Holdings based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Lixte Stock Analysis

When running Lixte Biotechnology's price analysis, check to measure Lixte Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lixte Biotechnology is operating at the current time. Most of Lixte Biotechnology's value examination focuses on studying past and present price action to predict the probability of Lixte Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lixte Biotechnology's price. Additionally, you may evaluate how the addition of Lixte Biotechnology to your portfolios can decrease your overall portfolio volatility.